[1]郑辉 常宝成 葛焕琦.3'-碘甲状腺原氨酸:保护心脏和调节代谢的新武器[J].国际内分泌代谢杂志,2019,39(02):140-127,140.[doi:10.3760/cma.j.issn.1673-4157.2019.02.013]
　Zheng Hui,Chang Baocheng,Ge Huanqi.3'-Iodothyronamine: a new weapon to protect the heart and regulate metabolism[J].International Journal of Endocrinology and Metabolism,2019,39(02):140-127,140.[doi:10.3760/cma.j.issn.1673-4157.2019.02.013]
点击复制

3'-碘甲状腺原氨酸:保护心脏和调节代谢的新武器()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年02期
页码:
140-127,140
栏目:
综述
出版日期:
2019-03-20

文章信息/Info

Title:
3'-Iodothyronamine: a new weapon to protect the heart and regulate metabolism
作者:
郑辉1 常宝成2 葛焕琦1
1泰达国际心血管病医院内分泌科,天津 300457; 2国家卫生健康委员会激素与发育重点实验室(天津医科大学),天津市代谢性疾病重点实验室,天津医科大学代谢病医院内分泌研究所 300070
Author(s):
Zheng Hui1;  Chang Baocheng2;  Ge Huanqi1
1TEDA International Cardiovascular Disease Hospital, Tianjin 300457, China; 2NHC Key Laboratory of Hormones and Development(Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, The Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China
关键词:
3'-碘甲状腺原氨酸;  心血管系统;  代谢;  肥胖
Keywords:
3'-Iodothyronamine;  Cardiovascular system;  Metabolism;  Obesity
DOI:
10.3760/cma.j.issn.1673-4157.2019.02.013
摘要:
3'-碘甲状腺原氨酸(T1AM)是新近发现的体内天然的甲状腺激素衍生物。它的合成机制尚不清楚。高效液相色谱-串联质谱法是体内检测T1AM的金标准。T1AM在体内分布广泛,通过与多种受体发挥生理学效应。T1AM能够改善心脏功能、减少心肌缺血-再灌注的损伤和心肌代谢,还能促进脂肪分解,降低体重,升高血糖,促进碳水化合物代谢向脂代谢转化。T1AM可能为治疗心力衰竭、肥胖、糖尿病提供新的靶点。
Abstract:
3'-Iodothyronamine(T1AM)is a recently discovered natural thyroid hormone derivative. The mechanism of its synthesis is not yet clear. The high performance liquid chromatography tandem mass spectrometry is the gold standard for the detection of T1AM in vivo. T1AM is widely distributed in vivo and exerts physiological effects through multiple receptors. T1AM can improve cardiac function, reduce myocardial ischemia reperfusion injury and myocardial metabolism and can also promote fat decomposition, reduce weight, increase blood glucose and promote carbohydrate metabolism to lipid metabolism. T1AM may provide new targets for the treatment of heart failure, obesity and diabetes.

参考文献/References:

[1] Hackenmueller SA,Marchini M,Saba A,et al.Biosynthesis of 3-iodothyronamine(T1AM)is dependent on the sodium-iodide symporterand thyroperoxidase but does not involve extrathyroidal metabolism of T4[J].Endocrinology,2012,153(11):5659-5667.DOI:10.1210/en.2012-1254.
[2] Galli E,Marchini M,Saba A,et al.Detection of 3-iodothyronamine in human patients:a preliminary study[J].J Clin Endocrinol Metab,2012,97(1):E69-E74.DOI:10.1210/jc.2011-1115.
[3] Hoefig CS,Köhrle J,Brabant G,et al.Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay[J].J Clin Endocrinol Metab,2011,96(6):1864-1872.DOI:10.1210/jc.2010-2680.
[4] Roy G,Placzek E,Scanlan TS.ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation[J].J Biol Chem,2012,287(3):1790-1800.DOI:10.1074/jbc.M111.275552.
[5] Dinter J,Khajavi N,Mühlhaus J,et al.The multitarget ligand 3-iodothyronamine modulates β-adrenergic receptor 2 signaling[J].Eur Thyroid J,2015,4(Suppl 1):21-29.DOI:10.1159/000381801.
[6] Dinter J,Mühlhaus J,Jacobi SF,et al.3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling[J].J Mol Endocrinol,2015,54(3):205-216.DOI:10.1530/JME-15-0003.
[7] Lucius A,Khajavi N,Reinach PS,et al.3-Iodothyronamine increases transient receptor potential melastatin channel 8(TRPM8)activity in immortalized human corneal epithelial cells[J].Cell Signal,2016,28(3):136-147.DOI: 10.1016/j.cellsig.2015.12.005.
[8] Ghanian Z,Maleki S,Reiland H,et al.Optical imaging of mitochondrial redox state in rodent models with 3-iodothyronamine[J].Exp Biol Med(Maywood),2014,239(2):151-158.DOI:10.1177/1535370213510252.
[9] Chiellini G,Frascarelli S,Ghelardoni S,et al.Cardiac effects of 3-iodothyronamine:a new aminergic system modulating cardiac function[J].FASEB J,2007,21(7):1597-1608.
[10] la Cour JL,Christensen HM,Köhrle J,et al.Association between 3-iodothyronamine(T1AM)concentrations and left ventricular function in chronic heart failure[J].J Clin Endocrinol Metab,2018,DOI:10.1210/jc.2018-01466.
[11] Gachkar S,Oelkrug R,Martinez-Sanchez N,et al.3-Iodothyronamine induces tail vasodilation through central action in male mice[J].Endocrinology,2017,158(6):1977-1984.DOI:10.1210/en.2016-1951.
[12] Haviland JA,Reiland H,Butz DE,et al.NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment[J].Obesity(Silver Spring),2013,21(12):2538-2544.DOI:10.1002/oby.20391.
[13] Manni ME,De Siena G,Saba A,et al.3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice[J].Br J Pharmacol,2012,166(2):650-658.DOI:10.1111/j.1476-5381.2011.01823.x.
[14] Braulke LJ,Klingenspor M,DeBarber A,et al.3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation[J].J Comp Physiol B,2008,178(2):167-177.
[15] Selen Alpergin ES,Bolandnazar Z,Sabatini M,et al. Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycysticovary syndrome with 3-iodothyronamine[J].Physiol Rep,2017,5(1):pii:e13097.DOI:10.14814/phy2.13097.
[16] Cumero S,Fogolari F,Domenis R,et al.Mitochondrial F(0)F(1)-ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone[J].Br J Pharmacol,2012,166(8):2331-2347.DOI:10.1111/j.1476-5381.2012.01958.x.
[17] Assadi-Porter FM,Reiland H,Sabatini M,et al.Metabolic reprogramming by 3-iodothyronamine(T1AM): a new perspective to reverse obesity through Co-Regulation of Sirtuin 4 and 6 expression[J].Int J Mol Sci,2018,19(5):pii:E1535. DOI:10.3390/ijms19051535.
[18] Mariotti V,Melissari E,Iofrida C,et al.Modulation of gene expression by 3-iodothyronamine: genetic evidence for a lipolytic pattern[J].PLoS One,2014,9(11):e106923.DOI:10.1371/journal.pone.0106923.
[19] Klieverik LP,Foppen E,Ackermans MT,et al.Central effects of thyronamines on glucose metabolism in rats[J].J Endocrinol,2009,201(3):377-386.DOI:10.1677/JOE-09-0043.
[20] Lehmphul I,Höefig CS,Köhrle J.3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism[J].Mol Cell Endocrinol,2018,460:219-228.DOI:10.1016/j.mce.2017.07.026.
[21] Ghelardoni S,Chiellini G,Frascarelli S,et al.Uptake and metabolic effects of 3-iodothyronamine in hepatocytes[J].J Endocrinol,2014,221(1):101-110.DOI:10.1530/JOE-13-0311.
[22] Ju H,Kim T,Chung CM,et al.Metabolic suppression by 3-iodothyronamine induced muscle cell atrophy via activation of FoxO-proteasome signaling and downregulation of Akt1-S6K signaling[J].Biol Pharm Bull,2017,40(5):576-582.DOI:10.1248/bpb.b16-00653.

备注/Memo

备注/Memo:
通信作者:郑辉, Email:zhui0123@163.com
Corresponding author: Zheng Hui, Email:zhui0123@163.com
更新日期/Last Update: 2019-03-20